 DURHAM, N.C.--BUSINESS WIRE--- DTIL ARCUS--Precision BioSciences, Inc. Nasdaq: DTIL a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on June 8, 2022 at 8:00 AM ET. We look forward to sharing the recent developments on our CAR T programs, including the latest clinical data on our potential first 